SETD1B
SETD1B (Histone-lysine N-methyltransferase SETD1B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Oesophageal cancer, Head and neck squamous cell carcinoma, Ovarian cancer and 5 more.
Overview
Histone methyltransferase that catalyses methyl group transfer from S-adenosyl-L-methionine to the epsilon-amino group of 'Lys-4' of histone H3 (H3K4) via a non-processive mechanism. Part of chromatin remodeling machinery, forms H3K4me1, H3K4me2 and H3K4me3 methylation marks at active chromatin sites where transcription and DNA repair take place. Plays an essential role in regulating the transcriptional programming of multipotent haematopoietic progenitor cells and lymphoid lineage specification during haematopoiesis.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 8 cohorts (1 activating, 7 loss-of-function), covering Oesophageal Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Lung Adenocarcinoma, Non-Small Cell Lung Cancer, Ovarian Epithelial Tumour, Pancreatic Adenocarcinoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · SETD1B (Histone-lysine N-methyltransferase SETD1B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Oesophageal cancer, Head and neck squamous cell carcinoma, Ovarian cancer and 5 more.
- 1 · What it is
SETD1B (Histone-lysine N-methyltransferase SETD1B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Oesophageal cancer, Head and neck squamous cell carcinoma, Ovarian cancer and 5 more.
- 2 · What goes wrong in cancer
Histone methyltransferase that catalyses methyl group transfer from S-adenosyl-L-methionine to the epsilon-amino group of 'Lys-4' of histone H3 (H3K4) via a non-processive mechanism.
- 3 · How drugs use it
No product in this corpus aims at SETD1B yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:29187 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9UPS6 (protein name, function text, keywords and locations (REST API)); CIViC gene SETD1B (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); IntOGen SETD1B (driver in 8 cohorts (Act 1, LoF 7); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Histone methyltransferase that catalyses methyl group transfer from S-adenosyl-L-methionine to the epsilon-amino group of 'Lys-4' of histone H3 (H3K4) via a non-processive mechanism. Part of chromatin remodeling machinery, forms H3K4me1, H3K4me2 and H3K4me3 methylation marks at active chromatin sites where transcription and DNA repair take place. Plays an essential role in regulating the transcriptional programming of multipotent haematopoietic progenitor cells and lymphoid lineage specification during haematopoiesis. Location: Nucleus; Nucleus speckle; Chromosome; Cytoplasm (UniProt). Locus 12q24.31 (HGNC).
- Oesophageal cancer: IntOGen driver in 1 cohort (ESCA)
- Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)
- Ovarian cancer: IntOGen driver in 1 cohort (OVT)
- Pancreatic ductal adenocarcinoma: IntOGen driver in 1 cohort (PAAD)
- Gastric & gastro-oesophageal junction cancer: IntOGen driver in 1 cohort (STAD)
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (UTUC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 7 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"SETD1B" OR ABSTRACT:"SETD1B" OR TITLE:"SET domain containing 1B, histone lysine methyltransferase" OR ABSTRACT:"SET domain containing 1B, histone lysine methyltransferase" OR TITLE:"Histone-lysine N-methyltransferase SETD1B" OR ABSTRACT:"Histone-lysine N-methyltransferase SETD1B" OR TITLE:"KIAA1076" OR ABSTRACT:"KIAA1076" OR TITLE:"Set1B" OR ABSTRACT:"Set1B" OR TITLE:"KMT2G" OR ABSTRACT:"KMT2G") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SETD1B, not a curated reading list.